SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending due to active investor speculation surrounding potential buyout rumors and an aggressive share buyback program that continues to reduce the float. The community remains deeply divided, with many bulls highlighting the stock's low price-to-earnings multiple as a deep-value opportunity, while frustrated traders express ongoing concern over stagnant price action and the company's competitive positioning.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing significant investor attention as the community debates its long-term potential in the MS market, focusing on the successful commercial launch of Briumvi and the strategic implications of upcoming subcutaneous dosing data. Discussions center on whether the company's growth trajectory and pipeline expansion make it a prime candidate for a high-premium buyout, or if management will continue building the business independently.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing heightened volatility and sharp price swings as investors weigh the company's massive cloud backlog and AI infrastructure investments against broader market concerns over tech-sector valuations and debt. The community is actively debating whether recent pullbacks represent a temporary shakeout of retail investors ahead of highly anticipated earnings, or if the stock is being unfairly penalized by institutional rotation and broader macro-driven selling.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as shares rally following a surge in May prediction market volumes, fueling community debate over the platform's role in future growth. Investors remain divided, with bulls highlighting expansion into new states as a long-term catalyst, while vocal critics focus on the stock's recent performance and ongoing management concerns.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors weigh its role as a critical supply chain partner to SpaceX and other aerospace giants against concerns over cash burn and potential dilution. The community remains deeply divided, with bulls pointing to the company's technical moats and anticipated earnings catalysts, while bears focus on high volatility, short interest dynamics, and the company's ongoing need for capital.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing significant volatility as market participants debate its role as a hedge against inflation and geopolitical uncertainty amid conflicting reports on international conflicts and aggressive selling pressure. The community remains deeply divided, with some investors aggressively accumulating on dips citing long-term industrial demand for electrification and AI, while others argue the metal is stuck in a corrective phase following a period of over-optimistic speculation.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as investors weigh strong institutional interest in its growing data center infrastructure against ongoing concerns regarding the CEO's communication strategy. While community members highlight the massive potential of the Helios campus, many are actively debating whether the stock is undervalued compared to its peers or if it remains held back by its heavy historical ties to crypto volatility.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is currently capturing investor attention as a structural outlier, holding steady at its gamma flip level while large-cap tech faces systematic repricing and heightened volatility. The market remains intensely focused on upcoming inflation data and potential Federal Reserve policy shifts, with traders closely debating whether the current rotation signals a rotation into small caps or a broader defensive positioning ahead of key macro catalysts.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp (UEC) is trending as investors focus on the company's production ramp-up at its Burke Hollow and Christensen Ranch projects amidst the broader nuclear energy sector's role in powering AI data centers. While the community is actively debating the stock's recent price volatility and institutional activity, sentiment remains heavily tied to the company's debt-free balance sheet and its strategic positioning within the domestic nuclear fuel supply chain.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as shares reach five-year highs following a significant patent extension for its lead drug, MIPLYFFA, through 2041. The community is actively discussing the company's strong fundamental position, analyst price target upgrades, and speculation regarding a potential buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now? 

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets. 

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +11.60% and -3.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Key PointsArk Invest added to existing positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday...

NTLA Q2 EPS Increased by Brookline Capital Markets

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at Brookline Capital Markets upped their Q2 2026 EPS estimates for Intellia Therapeutics in a report released on Wednesday, April 29th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.75...

Cathie Wood buys $14.1 million of megacap tech stock

Cathie Wood, chief of Ark Investment Management, often trades during earnings season.This time, the timing worked. She picked up shares of a megacap tech company just before results, and the stock...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

NTLAIntellia Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NTLA News